Free Trial

Elite Pharmaceuticals (ELTP) Short Interest Ratio & Short Volume

Elite Pharmaceuticals logo
$0.42 0.00 (-0.24%)
As of 05/2/2025 03:59 PM Eastern

Elite Pharmaceuticals Short Interest Data

Elite Pharmaceuticals (ELTP) has a short interest of 1.99 million shares, representing 0.22% of the float (the number of shares available for trading by the public). This marks a 1.02% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.7, indicating that it would take 0.7 days of the average trading volume of 947,965 shares to cover all short positions.

Current Short Interest
1,988,500 shares
Previous Short Interest
1,968,400 shares
Change Vs. Previous Month
+1.02%
Dollar Volume Sold Short
$845,907.90
Short Interest Ratio
0.7 Days to Cover
Last Record Date
April 15, 2025
Outstanding Shares
1,068,363,000 shares
Short Percent of Float
0.22%
Today's Trading Volume
419,100 shares
Average Trading Volume
947,965 shares
Today's Volume Vs. Average
44%
Short Selling Elite Pharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Elite Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ELTP Short Interest Over Time

ELTP Days to Cover Over Time

ELTP Percentage of Float Shorted Over Time

Elite Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/15/20251,988,500 shares $845,907.90 +1.0%0.2%0.7 $0.43
3/31/20251,968,400 shares $856,254.00 -0.8%0.2%1.6 $0.44
3/15/20251,984,000 shares $960,057.60 +0.1%0.2%1.7 $0.48
2/28/20251,982,000 shares $970,981.80 -5.8%0.2%1 $0.49
2/15/20252,105,000 shares $1.12 million +3.6%0.2%0.8 $0.53
1/31/20252,031,600 shares $1.02 million +3.0%N/A1.3 $0.50
1/15/20251,972,500 shares $946,800.00 -1.8%N/A0.6 $0.48
12/31/20242,008,300 shares $1.09 million -26.1%N/A0.8 $0.54
12/15/20242,717,700 shares $1.34 million +7.6%N/A0.9 $0.49
11/30/20242,526,500 shares $1.49 million +52.7%N/A0.5 $0.59
11/15/20241,654,500 shares $929,001.75 +6.0%N/A0.4 $0.56
10/31/20241,560,500 shares $692,549.90 -22.1%N/A0.1 $0.44
10/15/20242,004,100 shares $883,006.46 -1.6%N/A0.6 $0.44
9/30/20242,036,000 shares $789,968.00 -7.3%N/A0.6 $0.39
9/15/20242,195,500 shares $790,599.55 +19.7%N/A0.2 $0.36
8/31/20241,834,800 shares $507,597.42 +10.5%N/A0.3 $0.28
8/15/20241,661,100 shares $317,436.21 +5.0%N/A1 $0.19
7/31/20241,581,500 shares $294,159.00 -9.2%N/A1.4 $0.19
7/15/20241,740,800 shares $330,752.00 +7.1%N/A1 $0.19
6/30/20241,625,700 shares $323,514.30 +4.8%N/A1 $0.20
6/15/20241,550,800 shares $261,092.69 -2.4%N/A2.4 $0.17
5/31/20241,588,700 shares $274,845.10 +3.8%N/A1.3 $0.17
5/15/20241,530,700 shares $214,144.93 -4.1%N/A1.3 $0.14
4/30/20241,595,900 shares $207,147.82 -0.3%N/A1.8 $0.13
4/15/20241,601,300 shares $216,175.50 +2.9%N/A1.4 $0.14
3/31/20241,555,700 shares $240,106.74 -7.7%N/A1.4 $0.15
3/15/20241,684,700 shares $234,173.30 +5.1%N/A0.9 $0.14
2/29/20241,602,900 shares $258,066.90 +0.9%N/A0.4 $0.16
2/15/20241,588,800 shares $293,769.12 +75.2%N/A0.5 $0.18
1/15/2024103,200 shares $18,008.40 +24.8%N/A0 $0.17
12/31/202382,700 shares $11,578.00 No ChangeN/A0 $0.14
11/30/202380,600 shares $11,084.11 +58.4%N/A0 $0.14
11/15/202350,900 shares $7,380.50 No ChangeN/A0 $0.15
10/15/2023228,000 shares $21,831.00 +113.5%N/A0.3 $0.10
9/30/2023106,800 shares $10,019.44 +862.2%N/A0.1 $0.09
9/15/202311,100 shares $865.80 -94.8%N/A0 $0.08
8/31/2023211,700 shares $18,629.60 +1,283.7%N/A0 $0.09
8/15/202315,300 shares $711.45 -74.6%N/A0 $0.05
7/31/202360,300 shares $2,532.60 +102.4%N/A0 $0.04
7/15/202329,800 shares $1,132.40 No ChangeN/A0 $0.04
Shocking AI play that’s beats Nvidia by a country mile (Ad)

You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
6/15/202311,000 shares $374.00 -7.6%N/A0 $0.03
5/31/202311,900 shares $367.71 +643.8%N/A0 $0.03
5/15/20231,600 shares $49.44 -85.7%N/A0 $0.03
4/30/202311,200 shares $369.60 +3,633.3%N/A0 $0.03
4/15/2023300 shares $9.30 -93.6%N/A0 $0.03
3/31/20234,700 shares $136.30 +193.8%N/A0 $0.03
3/15/20231,600 shares $50.40 -20.0%N/A0 $0.03
2/28/20232,000 shares $71.20 -95.5%N/A0 $0.04
2/15/202344,200 shares $1,701.70 +44.9%N/A0.1 $0.04
1/31/202330,500 shares $1,030.90 +74.3%N/A0 $0.03
1/15/202317,500 shares $525.00 +2,087.5%N/A0 $0.03
12/30/2022800 shares $23.60 +700.0%N/A0 $0.03
12/15/2022100 shares $3.00 -99.0%N/A0 $0.03
11/30/202210,000 shares $329.00 -54.3%N/A0 $0.03
11/15/202221,900 shares $755.55 +1,268.8%N/A0.1 $0.03
10/31/20221,600 shares $57.28 -96.3%N/A0 $0.04
10/15/202242,800 shares $1,326.80 No ChangeN/A0 $0.03
9/15/2022400 shares $14.40 -99.4%N/A0 $0.04
8/31/202269,300 shares $2,477.48 -2.8%N/A0 $0.04
8/15/202271,300 shares $3,208.50 No ChangeN/A0.1 $0.05
7/15/20221,000 shares $42.90 -83.1%N/A0 $0.04
6/30/20225,900 shares $295.00 No ChangeN/A0 $0.05
5/31/20222,700 shares $123.39 No ChangeN/A0 $0.05
4/15/202216,900 shares $611.44 No ChangeN/A0 $0.04
2/28/2022212,900 shares $8,516.00 +3,030.9%N/A0.2 $0.04
2/15/20226,800 shares $289.00 -89.5%N/A0 $0.04
1/31/202264,500 shares $2,547.75 No ChangeN/A0.1 $0.04
12/31/2021100 shares $3.31 No ChangeN/A0 $0.03
12/15/2021100 shares $3.70 -99.6%N/A0 $0.04
11/30/202124,600 shares $883.14 +24,500.0%N/A0 $0.04
11/15/2021100 shares $3.82 -98.9%N/A0 $0.04
10/29/20219,400 shares $362.84 -38.2%N/A0 $0.04
10/15/202115,200 shares $608.00 +280.0%N/A0 $0.04
9/30/20214,000 shares $172.00 No ChangeN/A0 $0.04
8/31/202111,500 shares $543.95 +8.5%N/A0 $0.05
8/13/202110,600 shares $484.42 -46.7%N/A0 $0.05
7/30/202119,900 shares $953.21 +74.6%N/A0 $0.05
7/15/202111,400 shares $550.62 No ChangeN/A0 $0.05
6/15/202112,200 shares $668.56 No ChangeN/A0 $0.05
5/14/202121,600 shares $1,252.80 +151.2%N/A0 $0.06
4/30/20218,600 shares $467.41 No ChangeN/A0 $0.05
3/31/20211,500 shares $87.00 -89.2%N/A0 $0.06
3/15/202113,900 shares $847.90 -65.6%N/A0 $0.06
2/26/202140,400 shares $2,585.60 +1,054.3%N/A0 $0.06
2/12/20213,500 shares $261.80 +218.2%N/A0 $0.07
1/29/20211,100 shares $64.35 -83.3%N/A0 $0.06
12/31/202012,500 shares $675.00 No ChangeN/A0 $0.05
11/30/202027,400 shares $1,479.60 -68.4%N/A0 $0.05
11/15/202086,700 shares $6,675.90 No ChangeN/A0.1 $0.08
10/15/202012,100 shares $847.00 No ChangeN/A0 $0.07
Shocking AI play that’s beats Nvidia by a country mile (Ad)

You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
8/31/202073,800 shares $5,830.20 +939.4%N/A0 $0.08
8/14/20207,100 shares $477.83 -92.6%N/A0 $0.07
7/31/202096,500 shares $6,031.25 +222.7%N/A0.1 $0.06
7/15/202029,900 shares $2,299.31 +121.5%N/A0 $0.08
6/30/202013,500 shares $1,120.50 -59.0%N/A0 $0.08
6/15/202032,900 shares $2,961.00 No ChangeN/A0 $0.09
5/15/202022,200 shares $1,698.30 +27.6%N/A0 $0.08

ELTP Short Interest - Frequently Asked Questions

What is Elite Pharmaceuticals' current short interest?

Short interest is the volume of Elite Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 1,988,500 shares of ELTP short. 0.22% of Elite Pharmaceuticals' shares are currently sold short. Learn More on Elite Pharmaceuticals' current short interest.

What is a good short interest ratio for Elite Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ELTP shares currently have a short interest ratio of 1.0. Learn More on Elite Pharmaceuticals's short interest ratio.

What is a good short interest percentage for Elite Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.22% of Elite Pharmaceuticals' floating shares are currently sold short.

Is Elite Pharmaceuticals' short interest increasing or decreasing?

Elite Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,988,500 shares, an increase of 1.0% from the previous total of 1,968,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Elite Pharmaceuticals' short interest compare to its competitors?

0.22% of Elite Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Elite Pharmaceuticals: Arcutis Biotherapeutics, Inc. (13.58%), IDEAYA Biosciences, Inc. (13.20%), Apogee Therapeutics, Inc. (25.93%), Harmony Biosciences Holdings, Inc. (7.46%), Agios Pharmaceuticals, Inc. (6.31%), Disc Medicine, Inc. (12.51%), Indivior PLC (2.18%), Edgewise Therapeutics, Inc. (17.37%), ANI Pharmaceuticals, Inc. (12.86%), Vera Therapeutics, Inc. (12.42%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

What does it mean to sell short Elite Pharmaceuticals stock?

Short selling ELTP is an investing strategy that aims to generate trading profit from Elite Pharmaceuticals as its price is falling. ELTP shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Elite Pharmaceuticals?

A short squeeze for Elite Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ELTP, which in turn drives the price of the stock up even further.

How often is Elite Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ELTP, twice per month. The most recent reporting period available is April, 15 2025.




This page (OTCMKTS:ELTP) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners